Recovery starts with VERIS™

Published in Dermatologic Surgery, this randomized controlled trial (RCT) conducted by the Dermatology Department at Vanderbilt University Medical Center compared SweetBio®’s technology and secondary intention healing (SIH) to support wound closure post-Mohs. Results demonstrated improved wound healing with SweetBio®’s technology showing significant reduction in pain scores and favorable skin thickness.

Download

Published in The International Journal of Lower Extremity Wounds, this clinical evaluation involved 5 physicians across 4 states using SweetBio®’s technology to treat non-healing chronic ulcers. Patients achieved 100% closure within 8 weeks, with a mean closure time of 4.1 weeks.

Download

Published in Dermatologic Surgery, this clinical evaluation conducted by the Dermatology Department at Vanderbilt University Medical Center used SweetBio®’s technology to support wound closure post Mohs (skin cancer removal) surgery. Results demonstrated complete re-epithelialization was achieved within an average of 6 weeks.

Download

Published in Wounds, this retrospective IRB-approved clinical evaluation assessed chronic wound closure rates using standard of care (SOC) or treatment with SweetBio®’s technology in an urban hospital wound clinic. In both groups, most wounds did not close for several reasons, mainly patient compliance. For wounds that did close, the average time to closure was two times faster for SweetBio®’s technology compared to SOC (7.4 weeks and 14.8 weeks, respectively; p < .05).

Download

Auricular (ear) wounds following Mohs micrographic surgery (MMS) are challenging to manage due to limited soft tissue and the avascular nature of cartilage. Secondary intention healing (SIH) is commonly used but often requires 6–10 weeks for closure. A collagen–Mānuka honey– hydroxyapatite dressing (CHD) has been developed to support wound repair and may shorten healing time with favorable scarring outcomes. We report three auricular MMS cases managed with the CHD applied at home every 3–4 days under a hydrocolloid cover. Initial defects measured 6.25 cm², 3.61 cm², and 1.0 cm². All wounds demonstrated healthy granulation at two weeks and were epithelized by day 28 with minimal to no scarring. These results compare favorably with a recent multicenter study in which 54 auricular wounds treated with SIH had a mean healing time of 56.9 days. CHD-assisted SIH may reduce healing time, lower the need for clinic.

Download

Traumatic wounds present complex challenges due to tissue loss, contamination risk, and delayed healing, often requiring resource-intensive interventions such as negative pressure wound therapy, grafting, or repeated clinical visits. There remains an unmet need for affordable dressings that not only protect but also foster a stable wound environment and enable at-home management. The collagen–honey–hydroxyapatite dressing (CHD) combines collagen, Mānuka honey, and hydroxyapatite which are known to provide structural support, regulate inflammation, reduce bacterial burden, and promote angiogenesis and granulation. This case series reports outcomes in three patients with diverse traumatic wounds. Patient A, a healthy 26-year-old male with a puncture wound, achieved complete closure by Week 4. Patient B, an 88-year-old female with multiple comorbidities and a dog-scratch laceration, achieved closure by Week 6. Patient C, a 91-year-old male with a scalp wound complicated by prior radiation therapy and infection, demonstrated a 92% reduction in wound area by Week 4.5 despite travel-related treatment gaps. Across all cases, the CHD supported rapid granulation, wound stabilization, and steady progression toward closure, while enabling simplified at-home application. These findings suggest the CHD may represent a cost-effective, patient-centered alternative for traumatic wound management.

Download

Non-melanoma skin cancers commonly affect the lower extremities and scalp, where Mohs micrographic surgery (MMS) often leaves wounds with complex healing challenges due to limited vascularity, thin skin, and patient comorbidities. Secondary intention healing (SIH) remains a standard method but can result in prolonged recovery and suboptimal cosmetic outcomes. This case series evaluated a bioengineered collagen-honey-hydroxyapatite dressing (CHD) applied to eight post-Mohs wounds - five on the lower leg and three on the scalp - managed by SIH. Patients received the CHD through a durable medical equipment (DME) home-delivery model and self-applied the dressing at home per manufacturer guidelines. Healing progression was documented through before-and-after images and assessed qualitatively for granulation, re-volumization, erythema/inflammation, and epithelialization. Across all cases, CHD use was associated with visible wound improvement, including reduced depth, increased granulation tissue, diminished redness, and progressive closure, even in wounds with exposed fascia or periosteum. These real-world findings suggest that the CHD supports effective healing in post-Mohs surgical wounds managed by SIH and that the DME model improves accessibility and adherence among MMS patients. The CHD represents a practical, cost-effective, and patient-centered solution for enhancing wound outcomes in dermatologic surgery.  

Download